Schizophrenia Spectrum DisorderNETPSYCHNCT03730831
Childhood Maltreatment, Traumatic Experiences and Stress-associated Parameters in Schizophrenia Spectrum Disorders
A study testing Narrative Exposure Therapy in people with Schizophrenia Spectrum Disorder and PTSD, run by University of Konstanz at 1 site in Germany.
Trial summary
Childhood maltreatment (CM) in psychotic disorders is associated with increased cognitive deficits, severe psychotic symptoms, and increased comorbidity. The number of different stress experiences also increases the probability of trauma-associated symptoms. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Schizophrenia Spectrum Disorder, PTSD
- What is being tested?
- Narrative Exposure Therapy
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteGermany
- Study dates
- 1 Jan 2018to 24 Oct 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with schizophrenia spectrum disorder
- Patients with schizophrenia spectrum disorder and comorbid PTSD Diagnosis (DSM-5)
Who cannot join
- mental impairment (e.g. dementia)
- insufficient language comprehension
- non-compliance with appointments
Trial locations and contacts
1 site in 1 country.
Germany1 site
University of Konstanz, Psychotherapy Outpatient Clinic
Konstanz, 78464
About this study
Official title: Childhood Maltreatment, Traumatic Experiences and Stress-associated Parameters: Relationship and Influence on the Course of Illness in Schizophrenia Spectrum Disorders
Childhood maltreatment (CM) in psychotic disorders is associated with increased cognitive deficits, severe psychotic symptoms, and increased comorbidity. The number of different stress experiences also increases the probability of trauma-associated symptoms. Furthermore, neurobiological changes play a key role in the vulnerability of individuals with early traumas for mental and physical illnesses, among others for diseases of the schizophrenia spectrum disorder and the further course of the disease.
The project is divided into two work programs and pursues:
- A detailed recording of the course of symptoms in participants with schizophrenia spectrum disorder to link this data with a systematic recording of CM and traumatic experiences and biological data.
- On a subsample of participants with schizophrenia spectrum disorder and a comorbid post-traumatic stress disorder (PTSD), the researchers want to investigate whether symptom traits of existing psychotic disorders, trauma-associated symptoms and cognitive functions can be influenced by a trauma-specific treatment (NET), that has been proven to be effective in the treatment of PTSD.
Read the detailed description
Numerous scientific findings point to the influence of CM and traumatic experiences on the risk of mental and physical illnesses, their severity and their course. Traumatic experiences also increase the risk of demonstrating psychotic symptoms or even develop psychotic disorders. Furthermore, the number of different stress experiences also increases the probability of trauma-associated symptoms (symptoms of post-traumatic stress disorder (PTSD) and dissociative experiences).
Neurobiological changes in the immune system, the defense of stress and also central nervous circuits and structures play a key role in the vulnerability of individuals with early traumas for mental and physical illnesses, e.g. for diseases of the schizophrenia spectrum disorder and the further course of the disease.
The recording of stressful and traumatic life experiences has been largely neglected in everyday clinical practice, especially in patients with a schizophrenia spectrum disorder. The diagnosis of PTSD is rarely given in everyday clinical practice, so that trauma-specific treatment is often not offered.
The targeted use of a scientifically proven intervention to reduce the symptoms of PTSD (NET: Narrative Exposure Therapy) involves a change in stress-associated biomolecular parameters and normalizes neuronal brain activity.
The project pursues a systematic assessment of CM and traumatic experiences as well as a detailed recording of the course of symptoms in participants with schizophrenia spectrum disorder. Furthermore, in a subsample of participants with schizophrenia spectrum disorder and comorbid PTSD, the researchers want to investigate whether symptom traits of existing psychotic disorders, trauma-associated parameters and cognitive functions can be influenced by a trauma-specific treatment (NET).
The original research plan had to be modified because of the COVID-19 restrictions. Thus, during the course of the study, we had to modify design and data assessment.
The original plans related to the two work programs of the study and their modification are described below:
Work program 1 (WP1):
Originally, the WP1 included a weekly prospective assessment of psychotic symptoms on a sample of n=100 participants with schizophrenia spectrum disorder and planed to link this data with results from a cross-sectional assessment on traumatic and childhood maltreatment and biological data (cortisol awakening (CAR), diurnal cortisol profile, tonic cortisol concentration in hair and determination of mitochondrial respiratory activity in mononuclear cells).
Modifications of the original study plan of WP1:
- Originally, it was planned to examine the determination of mitochondrial respiratory activity in mononuclear cells. Due to a change in cooperation with a partner study project, examination of mitochondrial respiratory activity in mononuclear cells was later on excluded and focus was set only on the endocrine system via cortisol response (CAR, diurnal cortisol profiles and hair cortisol concentration).
- Due to the COVID pandemic, saliva samples could only be collected before pandemic restriction rules. Therefore, not all participants contributed in all parts of the originally planned WP1.
- Due to COVID restrictions, access to the study population was restricted and the planned total of n=100 could not be completed, instead n=79 patients could be included into the study.
- In addition to the patient data, we also collected data from healthy controls (n=39) to replicate existing findings between healthy controls and people with schizophrenia spectrum disorder.
- In addition to the clinical interview (cross-sectional assessment) of traumatic and childhood maltreatment, we included measurements of parental bonding (high/low parental care, high/low overprotection) to have a more detailed look on how childhood experiences can influence symptom course of psychotic disorders.
- The weekly assessment of psychotic symptoms did not proof to be feasible in daily clinical routine due to the high time consumption of assessments during COVID restrictions. Outcome measures therefore focused on three points in time, i.e. admission to study, 4 weeks after admission, and 3 months after admission or - if released earlier - at release from inpatient treatment.
The adapted WP1 pursued the following research questions:
- What influence do childhood maltreatment and traumatic experiences have on current psychological and physical well-being (systematic \& detailed symptom recording)?
- What influence does the family atmosphere have on the illness course?
- Do parameters of the stress hormone system (wake-up cortisol, diurnal cortisol profile, hair cortisol concentration) correlate with measures of past childhood maltreatment, traumatic experiences, and parental bonding? Work program 2 (WP2): The second work program originally focussed on the subgroup of WP1 participants with schiziphrenia spectrum disorder and comorbid PTSD. It was planned to conduct a randomized controlled pilot study with n=20 to determine the impact of trauma-focused therapy (NET) on the course of symptoms. In addition to the symptoms of PTSD, psychosis-specific parameters such as cognitive functions and biological characteristics were planned to be repeatedly recorded (pre, post, 6 months and 12 months after completing trauma therapy). Modifications of the original study plan of WP2:
- Originally, a randomized control pilot study was planned with n=20 participants randomly allocated to either an active intervention group (n=10, receiving NET additionally to care as usual) or to a no treatment group (care as usual; n=10). Due to restricted manpower and lowered feasibility in clinical daily routine during COVID, our study design had to be adapted and the control group had to be omitted. In stead, we conducted a case series of the 10 cases who received the active treatment. The adapted study, therefore, had a single-group, pre-test, post-test, and follow-up-test design.
- We planned to implement 6-10 trauma therapy sessions of 90 minutes per case. Due to the specific nature of psychotic disorders (e.g., conceptual disorganization or limited cognitive capacities), the NET routine had to be adapted. For example, the length of the sessions often had to be shortened, which led in most cases to a higher number of sessions as planned (on average 15-20 sessions). For more details, see our publication: Breinlinger, S., Pütz, A.-K., Stevens, N. R., Mier, D., Schalinski, I., \& Odenwald, M. (2020). Narrative Exposure Therapy in challenging cases and conditions. Maltrattamento e Abuso All'Infanzia: Rivista Interdisciplinare, 22(3), 37-50. https://doi.org/10.3280/MAL2020-003004.
- Furthermore, the follow-up assessment was changed to only pre (T0), post (T1) and 6 month follow-up (T2, 6 months after completing NET) for all measurements (PTSD symptoms, dissociation, cognitive functions, psychotic symptoms, depression, suicidal tendencies, quality of life).
- In the longitudibal course of WP2, biological data were only assessed at T1 (see reasons above relating to COVID pandemic). Instead, focus was set on clinical parameters: Primary outcomes were diagnosis, symptom severity of PTSD and dissociation assessed at T0, T1 and T2. Secondary outcomes were depressive symptoms, psychotic symptoms, suicidal tendencies, quality of life and cognitive performance measured by a standardized test battery. Single t-tests were used for data analysis. WP2 therefore pursued the following research questions:
- What changes of trauma-related and psychotic symptoms can be observed in patients with schizophrenia spectrum disorder and PTSD after a specific PTSD treatment module?
Giving the division of the work program in a cross sectional and a prospective part, our original study title "Narrative Exposure Therapy in Patients With Psychotic Disorders and a Posttraumatic Stress Disorder" included only WP2. In order to place both work programs in an overall context, the overall title was changed to:
"Childhood maltreatment, traumatic experiences and stress-associated parameters: Relationship and influence on the course of illness in schizophrenia spectrum disorders."
- Conditions
- Schizophrenia Spectrum Disorder, PTSD
- Being tested
- Narrative Exposure Therapy
- Keywords
- Course, Schizophrenia Spectrum Disorder, Posttraumatic Stress Disorder, Narrative Exposure Therapy
- Medical subject headings
- Stress Disorders, Post-Traumatic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Narrative Exposure TherapyBehavioural
8-20 sessions: 1 lifeline session, 6-17 sessions narrative exposure, 1-2 sessions of future-oriented counselling
-> Intervention is a part of the second work program. First work program focueses on cross-sectional data and includes a systematic record of psychopathology in participants with schizophrenia sepctrum disorder.
| Study group | Role | What they receive |
|---|---|---|
| Intervention (second work program) | Experimental | Narrative Exposure Therapy Narrative Exposure Therapy (NET) is a brief manualized trauma-focussed psychotherapeutic treatment and will be performed according to the manual of Schauer et al., 2011. In NET, traumatic experiences are worked through and placed in the context of the entire life story. Receives: Behavioral: Narrative Exposure Therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
PTSD symptom severity (PCL-5)
PTSD symptoms are measured in interview process (reporting period: previous 4 weeks) with the PTSD Checklist - 5 (PCL-5; Weathers, Litz, et al., 2013).
Measured: 1st. work program: at baseline. 2nd work program: Change from baseline (T0) to post treatment (T1; 1 week after completing NET) and 6-month follow-up (T2, 6 months after completing NET)
Psychotic Symptom Severity
The course of psychotic symptoms is measured during inpatient treatment (from admission to study to release from inpatient treatment, typically for 6-8 weeks) with the Positive and Negative Syndrome Scale (PANSS; Kay, S. R., Fiszbein, A., \& Opfer, L. A. (1987).
Measured: 1st workprogram: Change from admission to 4 weeks and 3 months after admission or if earlier at release; 2nd workprogram: Change of psychotic symptoms from baseline (T0) to post (T1; 1 week after completingNET) and 6 months follow-up (T2)
Dissociation (Shut-D)
Dissociative symptoms are assessed using the Shutdown Dissociation Scale (Shut-D), which measures the frequency of symptoms such as fainting, blurred vision, dizziness, altered hearing or vision, numbness, paralysis, and others {Schalinski, 2015 #46}. Participants reported the frequency of these symptoms over the past 6 months on a scale from 0 (not at all) to 3 (several times a week), with a total score ranging from 0 to 39.
Measured: 1st. work program: at baseline. 2nd work program: Change from baseline (T0) to post-treatment (T1; 1 week after completing NET) and 6 months follow-up (T2; 6 months after completing NET)
Childhood maltreatment including parental bonding/family atmosphere
CM are assessed using the Maltreatment and Abuse Chronology of Exposure scale (MACE; {Teicher, 2015 #73}; German version KERF by {Isele, 2014 #44}) developed to retrospectively assess exposure to ten types of CM from infancy to age 18, encompassing abuse (such as physical, verbal, and non-verbal emotional abuse, witnessing interparental and sibling abuse, peer-related verbal abuse and physical bullying, and intra-, extra-familial, or peer-related sexual abuse) as well as emotional and physical neglect.
Measured: 1st and 2nd work program: at baseline.
cortisol awakening response (CAR), diurnal cortisol profile and corresponding hair cortisol concentration
During the first hour after awakening saliva samples will be repeatedly collected following the established procedure.
Measured: only 1st work program: CAR at awaking, 30, 45 and 60 minutes after awakening; at noon (directly before lunch) and in the evening (directly before dinner); Hair cortisol concentration once
Secondary outcomes (4)
MATRICS Consensus Cognitive Battery
Cognitive change is measures with the MATRICS Consensus Cognitive Battery (Nuechterlein et al., 2008)
Measured: only 2nd work program: Change in cognitive functions is measured at baseline (T0), post-treatment (T1; within 1 month after completing NET) and 6 months follow-up (T2; 6 months after completing NET)
Depression Severity
Changes in depressive symptoms measured with Beck DEpression Inventory revised (BDI-II)
Measured: 1st. workprogram: at baseline. 2nd work program: Change in depression severity is measured at baseline (T0), post-treatment (T1; within 1 week after completing NET) and 6 months follow-up (T2; 6 months after completing NET)
Suicidal tendenies
MINI International Neuropsychiatric Interview (M.I.N.I.), Suicidal Scale (Lecrubier et al., 1997)
Measured: 1st. workprogram: at baseline. 2nd work program: Change in suicidal tendencies is measured at baseline (T0), post-treatment (T1; within 1 week after completing NET) and 6 months follow-up (T2; 6 months after competing NET)
Changes in quality of life
WHO Disability Assessment Schedule (WHODAS 2.0; World Health Organization, 2010)
Measured: 1st. workprogram: at baseline. 2nd work program: Change in quality of life is measured at baseline (T0), post-treatment (T1; within 1 week after completing NET) and 6 months follow-up (T2; 6 months after completing NET)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Nov 2018
- Study start1 Jan 2018
- Primary completion24 Oct 2022
- Study completion24 Oct 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Schizophrenia Spectrum DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Konstanz
- Sponsor type
- University, hospital or other
- Collaborators
- Centre for Psychiatry Reichenau
- Responsible party
- Principal investigator, Michael Odenwald, University of Konstanz
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03730831
- Sponsor's protocol ID
- NET PSYCH 2018
- Acronym
- NETPSYCH
- Status last verified
- Aug 2024
- First submitted
- 5 Jul 2018
- Last updated
- 13 Aug 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ 3rd, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008 Feb;165(2):203-13. doi: 10.1176/appi.ajp.2007.07010042. Epub 2008 Jan 2.
PubMed 18172019Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76. doi: 10.1093/schbul/13.2.261.
PubMed 3616518
Study at a glance
From the registry record, last updated by the sponsor on 13 Aug 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Childhood Maltreatment, Traumatic Experiences and Stress-associated Parameters: Relationship and Influence on the Course of Illness in Schizophrenia Spectrum Disorders
- ClinicalTrials.gov ID
- NCT03730831
- Acronym / sponsor ID
- NETPSYCH / NET PSYCH 2018
- Conditions
- Schizophrenia Spectrum Disorder, PTSD
- Keywords
- Course, Schizophrenia Spectrum Disorder, Posttraumatic Stress Disorder, Narrative Exposure Therapy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 10 participants (actual)
- Lead sponsor
- University of KonstanzUniversity, hospital or other
- Collaborators
- Centre for Psychiatry Reichenau
- Study start
- 1 Jan 2018 (actual)
- Primary completion
- 24 Oct 2022 (actual)
- Study completion
- 24 Oct 2022 (actual)
- First posted
- 5 Nov 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Childhood maltreatment (CM) in psychotic disorders is associated with increased cognitive deficits, severe psychotic symptoms, and increased comorbidity. The number of different stress experiences also increases the probability of trauma-associated symptoms. Furthermore, neurobiological changes play a key role in the vulnerability of individuals with early traumas for mental and physical illnesses, among others for diseases of the schizophrenia spectrum disorder and the further course of the disease.
The project is divided into two work programs and pursues:
- A detailed recording of the course of symptoms in participants with schizophrenia spectrum disorder to link this data with a systematic recording of CM and traumatic experiences and biological data.
- On a subsample of participants with schizophrenia spectrum disorder and a comorbid post-traumatic stress disorder (PTSD), the researchers want to investigate whether symptom traits of existing psychotic disorders, trauma-associated symptoms and cognitive functions can be influenced by a trauma-specific treatment (NET), that has been proven to be effective in the treatment of PTSD.
Detailed description
Numerous scientific findings point to the influence of CM and traumatic experiences on the risk of mental and physical illnesses, their severity and their course. Traumatic experiences also increase the risk of demonstrating psychotic symptoms or even develop psychotic disorders. Furthermore, the number of different stress experiences also increases the probability of trauma-associated symptoms (symptoms of post-traumatic stress disorder (PTSD) and dissociative experiences).
Neurobiological changes in the immune system, the defense of stress and also central nervous circuits and structures play a key role in the vulnerability of individuals with early traumas for mental and physical illnesses, e.g. for diseases of the schizophrenia spectrum disorder and the further course of the disease.
The recording of stressful and traumatic life experiences has been largely neglected in everyday clinical practice, especially in patients with a schizophrenia spectrum disorder. The diagnosis of PTSD is rarely given in everyday clinical practice, so that trauma-specific treatment is often not offered.
The targeted use of a scientifically proven intervention to reduce the symptoms of PTSD (NET: Narrative Exposure Therapy) involves a change in stress-associated biomolecular parameters and normalizes neuronal brain activity.
The project pursues a systematic assessment of CM and traumatic experiences as well as a detailed recording of the course of symptoms in participants with schizophrenia spectrum disorder. Furthermore, in a subsample of participants with schizophrenia spectrum disorder and comorbid PTSD, the researchers want to investigate whether symptom traits of existing psychotic disorders, trauma-associated parameters and cognitive functions can be influenced by a trauma-specific treatment (NET).
The original research plan had to be modified because of the COVID-19 restrictions. Thus, during the course of the study, we had to modify design and data assessment.
The original plans related to the two work programs of the study and their modification are described below:
Work program 1 (WP1):
Originally, the WP1 included a weekly prospective assessment of psychotic symptoms on a sample of n=100 participants with schizophrenia spectrum disorder and planed to link this data with results from a cross-sectional assessment on traumatic and childhood maltreatment and biological data (cortisol awakening (CAR), diurnal cortisol profile, tonic cortisol concentration in hair and determination of mitochondrial respiratory activity in mononuclear cells).
Modifications of the original study plan of WP1:
- Originally, it was planned to examine the determination of mitochondrial respiratory activity in mononuclear cells. Due to a change in cooperation with a partner study project, examination of mitochondrial respiratory activity in mononuclear cells was later on excluded and focus was set only on the endocrine system via cortisol response (CAR, diurnal cortisol profiles and hair cortisol concentration).
- Due to the COVID pandemic, saliva samples could only be collected before pandemic restriction rules. Therefore, not all participants contributed in all parts of the originally planned WP1.
- Due to COVID restrictions, access to the study population was restricted and the planned total of n=100 could not be completed, instead n=79 patients could be included into the study.
- In addition to the patient data, we also collected data from healthy controls (n=39) to replicate existing findings between healthy controls and people with schizophrenia spectrum disorder.
- In addition to the clinical interview (cross-sectional assessment) of traumatic and childhood maltreatment, we included measurements of parental bonding (high/low parental care, high/low overprotection) to have a more detailed look on how childhood experiences can influence symptom course of psychotic disorders.
- The weekly assessment of psychotic symptoms did not proof to be feasible in daily clinical routine due to the high time consumption of assessments during COVID restrictions. Outcome measures therefore focused on three points in time, i.e. admission to study, 4 weeks after admission, and 3 months after admission or - if released earlier - at release from inpatient treatment.
The adapted WP1 pursued the following research questions:
- What influence do childhood maltreatment and traumatic experiences have on current psychological and physical well-being (systematic \& detailed symptom recording)?
- What influence does the family atmosphere have on the illness course?
- Do parameters of the stress hormone system (wake-up cortisol, diurnal cortisol profile, hair cortisol concentration) correlate with measures of past childhood maltreatment, traumatic experiences, and parental bonding? Work program 2 (WP2): The second work program originally focussed on the subgroup of WP1 participants with schiziphrenia spectrum disorder and comorbid PTSD. It was planned to conduct a randomized controlled pilot study with n=20 to determine the impact of trauma-focused therapy (NET) on the course of symptoms. In addition to the symptoms of PTSD, psychosis-specific parameters such as cognitive functions and biological characteristics were planned to be repeatedly recorded (pre, post, 6 months and 12 months after completing trauma therapy). Modifications of the original study plan of WP2:
- Originally, a randomized control pilot study was planned with n=20 participants randomly allocated to either an active intervention group (n=10, receiving NET additionally to care as usual) or to a no treatment group (care as usual; n=10). Due to restricted manpower and lowered feasibility in clinical daily routine during COVID, our study design had to be adapted and the control group had to be omitted. In stead, we conducted a case series of the 10 cases who received the active treatment. The adapted study, therefore, had a single-group, pre-test, post-test, and follow-up-test design.
- We planned to implement 6-10 trauma therapy sessions of 90 minutes per case. Due to the specific nature of psychotic disorders (e.g., conceptual disorganization or limited cognitive capacities), the NET routine had to be adapted. For example, the length of the sessions often had to be shortened, which led in most cases to a higher number of sessions as planned (on average 15-20 sessions). For more details, see our publication: Breinlinger, S., Pütz, A.-K., Stevens, N. R., Mier, D., Schalinski, I., \& Odenwald, M. (2020). Narrative Exposure Therapy in challenging cases and conditions. Maltrattamento e Abuso All'Infanzia: Rivista Interdisciplinare, 22(3), 37-50. https://doi.org/10.3280/MAL2020-003004.
- Furthermore, the follow-up assessment was changed to only pre (T0), post (T1) and 6 month follow-up (T2, 6 months after completing NET) for all measurements (PTSD symptoms, dissociation, cognitive functions, psychotic symptoms, depression, suicidal tendencies, quality of life).
- In the longitudibal course of WP2, biological data were only assessed at T1 (see reasons above relating to COVID pandemic). Instead, focus was set on clinical parameters: Primary outcomes were diagnosis, symptom severity of PTSD and dissociation assessed at T0, T1 and T2. Secondary outcomes were depressive symptoms, psychotic symptoms, suicidal tendencies, quality of life and cognitive performance measured by a standardized test battery. Single t-tests were used for data analysis. WP2 therefore pursued the following research questions:
- What changes of trauma-related and psychotic symptoms can be observed in patients with schizophrenia spectrum disorder and PTSD after a specific PTSD treatment module?
Giving the division of the work program in a cross sectional and a prospective part, our original study title "Narrative Exposure Therapy in Patients With Psychotic Disorders and a Posttraumatic Stress Disorder" included only WP2. In order to place both work programs in an overall context, the overall title was changed to:
"Childhood maltreatment, traumatic experiences and stress-associated parameters: Relationship and influence on the course of illness in schizophrenia spectrum disorders."
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Intervention (second work program) | Experimental | Behavioral: Narrative Exposure TherapyNarrative Exposure Therapy Narrative Exposure Therapy (NET) is a brief manualized trauma-focussed psychotherapeutic treatment and will be performed according to the manual of Schauer et al., 2011. In NET, traumatic experiences are worked through and placed in the context of the entire life story. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Patients with schizophrenia spectrum disorder
- Patients with schizophrenia spectrum disorder and comorbid PTSD Diagnosis (DSM-5)
Key exclusion criteria (3 listed)
- mental impairment (e.g. dementia)
- insufficient language comprehension
- non-compliance with appointments
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Narrative Exposure Therapy8-20 sessions: 1 lifeline session, 6-17 sessions narrative exposure, 1-2 sessions of future-oriented counselling -> Intervention is a part of the second work program. First work program focueses on cross-sectional data and includes a systematic record of psychopathology in participants with schizophrenia sepctrum disorder. | Behavioural | Intervention (second work program) |
Primary outcome
PTSD symptom severity (PCL-5)
Time frame: 1st. work program: at baseline. 2nd work program: Change from baseline (T0) to post treatment (T1; 1 week after completing NET) and 6-month follow-up (T2, 6 months after completing NET)
PTSD symptoms are measured in interview process (reporting period: previous 4 weeks) with the PTSD Checklist - 5 (PCL-5; Weathers, Litz, et al., 2013).
Psychotic Symptom Severity
Time frame: 1st workprogram: Change from admission to 4 weeks and 3 months after admission or if earlier at release; 2nd workprogram: Change of psychotic symptoms from baseline (T0) to post (T1; 1 week after completingNET) and 6 months follow-up (T2)
The course of psychotic symptoms is measured during inpatient treatment (from admission to study to release from inpatient treatment, typically for 6-8 weeks) with the Positive and Negative Syndrome Scale (PANSS; Kay, S. R., Fiszbein, A., \& Opfer, L. A. (1987).
Dissociation (Shut-D)
Time frame: 1st. work program: at baseline. 2nd work program: Change from baseline (T0) to post-treatment (T1; 1 week after completing NET) and 6 months follow-up (T2; 6 months after completing NET)
Dissociative symptoms are assessed using the Shutdown Dissociation Scale (Shut-D), which measures the frequency of symptoms such as fainting, blurred vision, dizziness, altered hearing or vision, numbness, paralysis, and others {Schalinski, 2015 #46}. Participants reported the frequency of these symptoms over the past 6 months on a scale from 0 (not at all) to 3 (several times a week), with a total score ranging from 0 to 39.
Childhood maltreatment including parental bonding/family atmosphere
Time frame: 1st and 2nd work program: at baseline.
CM are assessed using the Maltreatment and Abuse Chronology of Exposure scale (MACE; {Teicher, 2015 #73}; German version KERF by {Isele, 2014 #44}) developed to retrospectively assess exposure to ten types of CM from infancy to age 18, encompassing abuse (such as physical, verbal, and non-verbal emotional abuse, witnessing interparental and sibling abuse, peer-related verbal abuse and physical bullying, and intra-, extra-familial, or peer-related sexual abuse) as well as emotional and physical neglect.
cortisol awakening response (CAR), diurnal cortisol profile and corresponding hair cortisol concentration
Time frame: only 1st work program: CAR at awaking, 30, 45 and 60 minutes after awakening; at noon (directly before lunch) and in the evening (directly before dinner); Hair cortisol concentration once
During the first hour after awakening saliva samples will be repeatedly collected following the established procedure.
4 secondary outcomes
MATRICS Consensus Cognitive Battery
Time frame: only 2nd work program: Change in cognitive functions is measured at baseline (T0), post-treatment (T1; within 1 month after completing NET) and 6 months follow-up (T2; 6 months after completing NET)
Depression Severity
Time frame: 1st. workprogram: at baseline. 2nd work program: Change in depression severity is measured at baseline (T0), post-treatment (T1; within 1 week after completing NET) and 6 months follow-up (T2; 6 months after completing NET)
Suicidal tendenies
Time frame: 1st. workprogram: at baseline. 2nd work program: Change in suicidal tendencies is measured at baseline (T0), post-treatment (T1; within 1 week after completing NET) and 6 months follow-up (T2; 6 months after competing NET)
Changes in quality of life
Time frame: 1st. workprogram: at baseline. 2nd work program: Change in quality of life is measured at baseline (T0), post-treatment (T1; within 1 week after completing NET) and 6 months follow-up (T2; 6 months after completing NET)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Aug 2024.
- Background: PubMed 18172019Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ 3rd, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008 Feb;165(2):203-13. doi: 10.1176/appi.ajp.2007.07010042. Epub 2008 Jan 2.
- Background: PubMed 3616518Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76. doi: 10.1093/schbul/13.2.261.
- Individual participant dataSharing planned: Undecided
Related trials for Schizophrenia Spectrum Disorder
RecruitingPhase 3
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Schizophrenia, Autism-Related Irritability
Not yet recruitingObservational study
Sleep Monitoring for Early Detection of Relapse in People With Schizophrenia or Bipolar Disorder Receiving Usual Treatment
Bipolar Disorder (BD), SCHIZOPHRENIA 1 (Disorder)
Not yet recruitingPhase 1
Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants
Healthy Adult Participants
Active, not recruiting
Designing and Evaluating a Classroom-Based Mental Health Programme for Adolescents.
Mental Health Promotion
Recruiting
MI-CBTech: A Mobile Intervention for Community Integration in Homeless-Experienced Veterans With SMI
Schizophrenia Spectrum Disorders, Psychotic Affective Disorders
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Narrative Exposure Therapy in people with Schizophrenia Spectrum Disorder and PTSD, run by University of Konstanz at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
PTSD symptom severity (PCL-5) (time frame: 1st. work program: at baseline. 2nd work program: Change from baseline (T0) to post treatment (T1; 1 week after completing NET) and 6-month follow-up (T2, 6 months after completing NET)). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03730831, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2024.